logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Conbercept for neovascular age-related macular degeneration

< Back

Conbercept for neovascular age-related macular degeneration

Drugs

May 2021


Conbercept is currently in clinical development for treatment of adults (≥ 50 years old) with Neovascular age-related macular degeneration (AMD), also known as wet AMD, a chronic eye disease. This disease is characterised by the formation of immature blood vessels that grow between the retina (macula; a layer of tissue in the back of the eye that senses light and sends images to the brain). Such blood vessels easily haemorrhage and cause scarring, which leads to vision impairment and is a leading cause of central sight loss and blindness. Conbercept is a novel protein that is administered via injection into the eye (intravitreal injection). Its main function is to inhibit the vascular endothelial growth factor (VEGF), a protein that promotes he growth of new blood vessels. As conbercept blocks VEGF it leads to reduced growth of the abnormal blood vessels to treat neovascular AMD. If licensed, Conbercept may offer an additional treatment option for patients with neovascular AMD.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Get Alerts